Blair William & Co. IL Acquires 37,215 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Blair William & Co. IL increased its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 62.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 96,565 shares of the company’s stock after buying an additional 37,215 shares during the period. Blair William & Co. IL’s holdings in Teva Pharmaceutical Industries were worth $2,080,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. CWM LLC lifted its position in shares of Teva Pharmaceutical Industries by 315,000.0% in the 3rd quarter. CWM LLC now owns 6,302 shares of the company’s stock worth $136,000 after purchasing an additional 6,300 shares during the period. MAI Capital Management acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $204,000. FNY Investment Advisers LLC lifted its position in shares of Teva Pharmaceutical Industries by 989,900.0% in the 3rd quarter. FNY Investment Advisers LLC now owns 9,900 shares of the company’s stock worth $213,000 after purchasing an additional 9,899 shares during the period. Greenleaf Trust acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $215,000. Finally, Highstreet Asset Management Inc. lifted its position in shares of Teva Pharmaceutical Industries by 244.6% in the 3rd quarter. Highstreet Asset Management Inc. now owns 9,986 shares of the company’s stock worth $215,000 after purchasing an additional 7,088 shares during the period. Institutional investors and hedge funds own 61.66% of the company’s stock.

A number of research analysts have recently issued reports on TEVA shares. Mizuho boosted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, September 17th. Wells Fargo & Co set a $23.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Monday, September 17th. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the stock an “underperform” rating in a research report on Friday, November 2nd. Cantor Fitzgerald set a $25.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Friday, September 14th. Finally, Goldman Sachs Group upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 price target on the stock in a research report on Monday, October 1st. Three investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $21.94.

Teva Pharmaceutical Industries stock opened at $20.26 on Friday. The company has a debt-to-equity ratio of 1.75, a quick ratio of 0.61 and a current ratio of 0.94. Teva Pharmaceutical Industries Ltd has a 12-month low of $14.38 and a 12-month high of $25.96. The firm has a market cap of $20.90 billion, a P/E ratio of 5.16, a P/E/G ratio of 6.20 and a beta of 0.74.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The company had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.54 billion. During the same quarter in the previous year, the company earned $1.00 EPS. Teva Pharmaceutical Industries’s quarterly revenue was down 19.4% compared to the same quarter last year. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd will post 2.82 EPS for the current fiscal year.

In other Teva Pharmaceutical Industries news, insider Deborah A. Griffin sold 2,376 shares of the business’s stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $23.71, for a total transaction of $56,334.96. Following the completion of the sale, the insider now owns 2,376 shares in the company, valued at approximately $56,334.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Richard Daniell sold 2,488 shares of the business’s stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $23.69, for a total transaction of $58,940.72. Following the sale, the vice president now owns 2,488 shares of the company’s stock, valued at approximately $58,940.72. The disclosure for this sale can be found here. Insiders have sold a total of 7,464 shares of company stock worth $173,051 in the last quarter. 0.43% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Blair William & Co. IL Acquires 37,215 Shares of Teva Pharmaceutical Industries Ltd (TEVA)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/12/07/blair-william-co-il-acquires-37215-shares-of-teva-pharmaceutical-industries-ltd-teva.html.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Why do companies issue stock splits?

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply